Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Influenza Therapeutics Market Report 2017-2025 - CAGR to Grow by 7.8% Allowing the Market to Reach $6 Billion -

Research and Markets
Posted on: 23 Mar 18

The "Global Influenza Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to's offering.

The global Influenza therapeutics market was valued at US$ 6001.2 Million in 2016, and is expected to reach US$ 1204.1 Million by 2025, expanding at a CAGR of 7.8% from 2017 to 2025.

Global influenza market will grow significantly during the forecast period due to growing incidence of influenza worldwide, government initiatives in awareness and diagnostic programs are primarily driving the growth of influenza therapeutics market globally.

For the purpose of study, market is segmented on the basis of therapy type such as vaccines (trivalent and quadrivalent) and drugs (zanamivir, oseltamivir, peramivir and other). Currently, influenza vaccines (also known as flu shots or jabs) dominate the global influenza market because government initiative for vaccination is prime factor that is driving the growth of influenza vaccine market globally; The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), The European Centre for Disease Prevention and Control recommends yearly vaccination for nearly all people over the age of six months, especially those at high risk.

Key Topics Covered

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Influenza Therapeutics Market Analysis

Chapter 4 Global Influenza Therapeutics Market, by Therapy Type

Chapter 5 Global Influenza Therapeutics Market, by Geography

Chapter 6 Company Profiles
6.1 Abbott Laboratories
6.2 Astrazeneca PLC
6.3 Biocryst Pharmaceuticals Inc.
6.4 Chiron Corporation
6.5 CSL Limited
6.6 Daiichi Sankyo Co. Ltd.
6.7 Glaxosmithkline PLC
6.8 Mitsubishi Tanabe Pharma Corporation
6.9 Nanotherapeutics Inc.
6.10 Protein Sciences Corporation
6.11 Roche Holding AG
6.12 Sanofi SA
6.13 Shionogi & Co. Ltd.
6.14 Sinovac Biotech Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 23/03/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.